LEXINGTON, Mass., June 20, 2025 /PRNewswire/ -- Partner Therapeutics, Inc. (PTx) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended approval of PTx's Marketing Authorisation Application (MAA) for IMREPLYS®...
Hence then, the article about european medicines agency chmp recommends eu approval of partner therapeutics imreplys sargramostim rhu gm csf to treat exposure to myelosuppressive doses of radiation haematopoietic sub syndrome of acute radiation syndrome was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( European Medicines Agency CHMP Recommends EU Approval of Partner Therapeutics IMREPLYS® (sargramostim, rhu GM-CSF) to Treat Exposure to Myelosuppressive Doses of Radiation (Haematopoietic Sub-syndrome of Acute Radiation Syndrome) )
Also on site :
- Police called to multiple central Ohio schools after alleged bomb threats
- Doctors Are Seeing a Bizarre New COVID Symptom Right Now
- 3 questions every CEO needs to ask about the AI jobs doom loop in the wake of Jack Dorsey’s dramatic 40% layoffs at Block